Congress Presentations

Lonca Ph 2 Consolidation in LBCL with PR Post CAR-T [Planned Futility Analysis] | M. Hamilton

Consolidation with Loncastuximab Tesirine for Large B-cell Lymphoma Patients in Partial Response After CART: Planned Interim Futility Analysis of a Phase II Trial

Lonca-R followed by DA-R-EPOCH Untreated H-R DLBCL [Preliminary Results] | J. Hsieh-Wong

Efficacy and Safety of Loncastuximab tesirine and Rituximab (Lonca-R) Followed by DA-R-EPOCH in Previously Untreated High-Risk DLBCL: Preliminary Results from UCDCC#303, a UCHMC Phase II Trial

Lonca + Mosun in r/r DLBCL | SK. Thiruvengadam

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lonca Ph 2 in r/r MZL [Planned Interim Futility Analysis] | I. Lossos

Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma – Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study

Lonca + Venetoclax in r/r NHL | P Caimi

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Lonca Ph 2 Study in r/r WM | J. Castillo

A phase II trial of loncastuximab tesirine in patients with previously treated Waldenström macroglobulinemia

Lonca Ph 2 Consolidation in LBCL with PR at Day 30 Post CAR-T | A. Al Zaki

A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy

Glo-BNHL: Global Study of Novel Agents in Pediatric/Adolescent r/r B-NHL | E. Seaford

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)

ctDNA after Lonca for r/r DLBCL | D. Kurtz

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lonca in Chinese population in r/r DLBCL | N. Lin

Loncastuximab Tesirine Demonstrated Substantial Single-agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

LOTIS-2: Lonca CD19 Expression (QSP Modeling) | P. Caimi

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results From LOTIS-2 and Quantitative Systems Pharmacology Modeling

HEOR: RW Outcomes of Pola-BR or Tafa-Len by LOT | M. Hamadani

Real-world Outcomes in Relapse/Refractory DLBCL Patients Who Received Polatuzumab Vedotin Plus Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide by Line of Therapy

LOTIS-9: Lonca-R in Unfit/Frail w/ DLBCL [Trial-In-Progress Update] | J. Westin

A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab in Previously Untreated Unfit/Frail Patients With DLBCL (LOTIS-9)

Lonca Biomarkers r/r DLBCL using cfDNA-WGS | F. Vallania

Identification of predictive biomarkers for response of R/R DLBCL patients treated with loncastuximab tesirine using low-pass whole-genome cell-free DNA sequencing (cfDNA-WGS)

LOTIS-2: Lonca in r/r HGBCL | J. Alderuccio

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High‐Grade B‐Cell Lymphoma Treated with Loncastuximab Tesirine in the LOTIS‐2 Clinical Trial

Preclinical: Lonca w/ PARP Inhibitors - DNA Damage Boost | S. Fusani

CD19-mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP Inhibitors

LOTIS-2: Lonca in Post CAR-T | P. Caimi

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients With Diffuse Large B-Cell Lymphoma Who Relapsed After Anti-CD19 CAR T-Cell Therapy

Preclinical: Lonca + Pola in NHL | N. Sachini

Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma

HEOR: Treatment Patterns with 4L+ r/r DLBCL Post CAR-T | J. Xie

Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received ≥3 Lines of Therapies in Post CAR-T Era

LOTIS-3: Lonca + Ibrutinib in DLBCL or MCL [Interim Results] | J. Depaus

Interim Results of Loncastuximab Tesirine Combined With Ibrutinib in Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)

LOTIS-5: Lonca-R in r/r DLBCL [Trial-In-Progress] | Y. Linhares

Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma

Lonca Efficacy and Safety in r/r DLBCL | P. Caimi

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lonca Ph 2 in r/r DLBCL [Interim Futility Analysis] | C. Carlo-Stella

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

LOTIS-1: Lonca Exposure-Response in r/r nHL - PK | O. O'Connor

Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma